Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2025-12-17 @ 3:34 AM
Study NCT ID:
NCT06411691
Status:
None
Last Update Posted:
2025-12-03 00:00:00
First Post:
2024-05-08 00:00:00
Brief Title:
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Pancreatic Cancer |
| Colorectal Cancer |
Keywords:
| Name | View |
|---|---|
| Hiltonol | View |
| mKRAS peptide vaccines | View |
| Anti-PD-1 anti-check point inhibitor | View |
| PD-L1 check point inhibitor | View |
| Balstilimab | View |
| Botensilimab | View |
| Cancer Vaccines | View |
| SLP mKRASvax peptide vaccine Poly-ICLC Hiltonol | View |
| Immunotherapy | View |
| Colon Cancer | View |
| Metastatic colon cancer | View |
| Pancreatic Ductal Adenocarcinoma PDAC | View |
| Metastatic pancreatic cancer | View |